Automated Immunoassay Analyzers Market Analysis

Product (Immunofluorescence, Chemiluminescence, Enzyme Linked Fluorescent System, Radioimmunoassay)

The chemiluminescence segment has emerged as the leading product type in the automated immunoassay analyzers market and is expected to hold more than 37% share during the forecast period. This growth can be attributed to its superior sensitivity and specificity compared to other immunoassay techniques. Chemiluminescent analyzers find extensive applications in clinical laboratories for several studies related to hormone testing and infectious disease diagnosis. In March 2023, bioMérieux released the VIDAS SARS-CoV-2 IgG II, a chemiluminescent immunoassay, marking how continuous innovation in the segment is at the heart of pandemic management.

Application (Infectious Diseases, Endocrinology, Drug Monitoring, Chronic Diseases, Allergy Testing)

The infectious diseases segment in the automated immunoassay analyzers market is expected to register a steady revenue growth during the forecast period. This requirement for tools related to rapid and accurate diagnostics due to increasing global health concerns pertaining to infectious disease outbreaks such as COVID-19 has increased significantly. Their utilization in detecting and monitoring infectious diseases today provides timely information that is very helpful in making decisions about patients' treatments. Thus, these analyzers have turned out to be irreplaceable. Anbio Biotechnology Ltd. introduced the AF-100S FIA in July 2023 to strengthen its leading position in the point-of-care immunodiagnostic solution segment.

End user (Academic Research Institutes, Biotech and Pharma Companies, Hospitals, Diagnostic Test Laboratories, and Others)

The hospital segment is the largest end user category within the automated immunoassay analyzers market due to rising demand for high-throughput and precise diagnostic facilities within a hospital setup. An automated immunoassay analyzer can support a large number of tests in a very short span, which propels their integration into hospital diagnosis. In April 2023, Siemens Healthineers launched the Atellica Solution, a high degree of automation in an immunoassay system to address specific customer needs within large hospital laboratories, further strengthening the leading position of the segment.  

Our in-depth analysis of the automated immunoassay analyzers market includes the following segments: